{"name":"Lu Shun","slug":"lu-shun","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOUUM5ZTAzN01Pc3pXZ242a0kxcXQ1TlBmX3h2SlJvcGFWQUhqN1dpS2tfQU5QMFlYM09DZUctQXdtU0VUMDNCWkJpSnRabU96UFEzQUw1Y2hacmVkVHZVZzlJX3BSRlo3a3FLRkJlejRLMTZESWJkV0Q5bnZZa0FaaXNZRTJuaEJheDdXa3VWM0lJVkN1bHBKWk16M2UzLUNiVndZSUFEbVJjcXlMQUhyamZqZC1Sa0VnSy1qQ3BMSlF2XzZ0UVJxRTNnOFEzZm9lN3VrQzQyWndCVmJnT3BNMA?oc=5","date":"2025-11-25","type":"pipeline","source":"The ASCO Post","summary":"Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC - The ASCO Post","headline":"Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNbWpsclpENy1UYlA3V29LQ1BZd2V0M01DejBLZkZXRWtldXkxOFNSaWVOQlF5OVBCcFlJeU5GSngweXYyVmlsSnhRUEVoZFF1RWtsLXliTzdSSVhWR2lNbTlUdG15QkQ0eWlGaW9HR2JpZHB5SHFLa0ZTM01JZzVTN05zazNrS1FwQ0RwY2NybW16U3lmR0RVQ2JDSHd5ZGtLc1VRRGlCQVNBTXlUM2dMbjlZRnltUGxzcm5Za2V3eTRncy0wMG5TUw?oc=5","date":"2025-05-30","type":"regulatory","source":"BioPharma APAC","summary":"China Approves First Homegrown ADC, Trastuzumab Rezetecan, for HER2-Mutant Lung Cancer - BioPharma APAC","headline":"China Approves First Homegrown ADC, Trastuzumab Rezetecan, for HER2-Mutant Lung Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQX2V1M0ZucjhnbDhWdlBiYTBFWHNpaEJCZm40M1dtN3JnOGs2UXE0YmNPZE9aMmFGVS1MZkVUdW1PVDlvU2hycjQzWjkyVUN1SXhxc0xmX3FhMm1ERTR5SHhuVmJneUdhcTg1dkltemxqNmVlODc3MzVqVmVFTWt6aDVlMXo1Z25KT09MUXpZcjVCUENSUHAzckhOZzVyZ2xU?oc=5","date":"2025-04-23","type":"trial","source":"Fierce Pharma","summary":"With new trial win, Akeso bispecific shows prior success against Keytruda is no 'fluke' - Fierce Pharma","headline":"With new trial win, Akeso bispecific shows prior success against Keytruda is no 'fluke'","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBUTC14V2hTSnBSN1Z5Z0Y2ZElXY09vQW1maVl4YzctSVF2NGZfMWVwM0Z4bE1KR2xRSE1PZm5uSEs3d0F6ZVdaR3ktY0FBNnBuQnVj?oc=5","date":"2025-04-23","type":"trial","source":"FirstWord Pharma","summary":"Akeso, Summit's PD-1/VEGF bispecific records another pivotal study win in NSCLC - FirstWord Pharma","headline":"Akeso, Summit's PD-1/VEGF bispecific records another pivotal study win in NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQZEMxVUYyeGNMdkJRMDJoLU5tcWlkRF9QQmNqWU9NWm1aQi1GWElHekJkaFhNWnF2ek5yUEZMc0gtVlJVQ2hDakNVMnhZcVk5X0szVVlFM3JLS05rWWpPSzdxZGM1WUVtUWVfYl9KTnVHNXU3cE91YzlPTEdxcUFTRlQzRlJfS1ZuNUtJSmxpUks0cWdPZzNwSlZlbkJtNHhydFhKTHc1X09KSWtHdFpZN2JtZ3lYTnZubDRUdnpTMmF5cWRHV2Q0ajRHU1hOSG1wa0xyV0NqVlFsaWFCZjlvbk9jWQ?oc=5","date":"2025-04-23","type":"pipeline","source":"Pharmaceutical Executive","summary":"Akeso’s PD-1/VEGF Bispecific Antibody Demonstrates Meaningful Progression-Free Survival Benefits in Advanced Squamous NSCLC - Pharmaceutical Executive","headline":"Akeso’s PD-1/VEGF Bispecific Antibody Demonstrates Meaningful Progression-Free Survival Benefits in Advanced Squamous NS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBQM0JfU1NjYUhNTXRfYTFMc0hsRVpvODc2YXRsZ0VmWGltMXY4UFMxclJzU2VXR3FmY3hVYi1Nc3lHTEpVTl85bEc5ME1ZNndYX2xTTVVOMlktWjdOWXd5dFk0cVd3NU1NbDF0bmNFTGI1TGs?oc=5","date":"2025-02-26","type":"pipeline","source":"MedPage Today","summary":"Novel Drug Shrinks 73% of HER2-Mutant Lung Cancers - MedPage Today","headline":"Novel Drug Shrinks 73% of HER2-Mutant Lung Cancers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9sVDNTVTNrdjdpVHZBa2xSZ3ZCWW95d1lVaDY5ZHpZQ3NncElnYjdPUVBzc0NTMFF3NERDeXBlbUpBdVY4LWdBWGs4dWpJVlpib2hoLWwwT2NjRjNrVEM2Ug?oc=5","date":"2022-04-11","type":"pipeline","source":"NEJM","summary":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer - NEJM","headline":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9ESkY1TmttMElPTVZ6VWdhczJiRk5BZjhJNndsNXBtaW9INE1LemJHT0VSal9mbmFiRktLVTFtSmx2aFpYOWRpa0hxc0xLSV9LNGZWRWNtS1c0dGo2RkpCQjE0VmptQi1RamhB?oc=5","date":"2021-03-14","type":"pipeline","source":"The Wire China","summary":"The Soul of Lu Xun - The Wire China","headline":"The Soul of Lu Xun","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}